fig1

Figure 1. Overview of PSMD14-mediated mechanisms driving tumor progression and therapeutic resistance. PSMD14 deubiquitinates and stabilizes a broad range of substrate proteins, thereby regulating cell cycle progression, programmed cell death (ferroptosis and paraptosis), EMT, invasion and metastasis, mitochondrial function, and metabolic reprogramming. These concerted actions ultimately drive therapeutic resistance to chemotherapy, targeted or endocrine therapy, and proteasome inhibitors across multiple cancer types. Arrows indicate regulatory relationships, and ↑/↓ denote activation or suppression of the corresponding pathways or phenotypes. Created in BioRender. Liu, H. (2026) https://BioRender.com/j66f63i. EMT: Epithelial-mesenchymal transition; ERα: estrogen receptor α; AKT: protein kinase B; MYC: MYC proto-oncogene; HK2: hexokinase 2; LDHA: lactate dehydrogenase A; mTOR: mechanistic target of rapamycin; BCAA: branched-chain amino acid; HNSCC: head and neck squamous cell carcinoma; CRC: colorectal cancer; GBM: glioblastoma; OS: osteosarcoma; BC: breast cancer; MM: multiple myeloma.